<DOC>
	<DOCNO>NCT01311739</DOCNO>
	<brief_summary>The purpose study ass compare pharmacokinetics ( PK ) cyanocobalamin oral administration Eligen® B12 ( cyanocobalamin/SNAC ) , oral cyanocobalamin alone ( commercially-available formulation ) cyanocobalamin administer intravenously ( IV ) ( also commercially-available formulation ) healthy male subject fast condition . The safety tolerability oral Eligen® B12 ( cyanocobalamin/SNAC ) versus oral cyanocobalamin alone versus IV cyanocobalamin also assess .</brief_summary>
	<brief_title>Oral Cyanocobalamin ( Eligen B12 ) Bioavailability Study</brief_title>
	<detailed_description />
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<criteria>Healthy male subject age 18 45 year . Signed ICF prior studyrelated procedure . Normal organ function include renal hepatic function . Normal hematological function . Body weight 60 100 kg within 18 30 kg/m2 body mass index ( BMI ) . Normal range vital sign , ECG , laboratory test . Normal range serum B12 , methylmalonic acid ( MMA ) , homocysteine . Current use ( within 14 day ) acetaminophen nonsteroidal antiinflammatory drug ( NSAIDs ) ( i.e. , aspirin ibuprofen ) Current use ( within 14 day ) antibiotic , antacid , multivitamin , nutritional supplement . Absolute platelet count 100 x 109/L History current diagnosis clinically significant disease liver , kidneys GI system , abnormal condition compromise function system could result possibility alter absorption , excess accumulation , impairment metabolism excretion study product . History current diagnosis clinically significant hematological , immunological , metabolic , cardiovascular , neurological , GI abnormality , opinion Investigator exclude subject study . Any clinically significant laboratory value Screening , , opinion Investigator , suggest condition could preclude subject enter study . At risk transmit infection via blood sample e.g. , produce positive HIV test screening participate highrisk activity contract HIV ; produce positive HBsAg test screening ; produce positive hepatitis C antibody test screening . Participation clinical research study involve new chemical entity within 30 day study entry . Significant loss donation blood within 56 day plasma within 30 day prior initial dose study . Unsuitable reason receive study product opinion Investigator . Alcohol consumption within last 48 hour prior study entry anytime study . Positive urine alcohol test .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>